Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over rivals from Amgen and Novartis.
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback